PIN-Cocktail 1

The combination of AMACR and p63 may be very useful for diagnosing PIN and small focal adenocarcinoma, especially in difficult cases and cases with limited tissue. This antibody mix can eliminate the need for 34bE12. AMACR stains the cytoplasm in prostate adenocarcinoma and PIN, while p63 stains the basal cell nucleus in PIN and benign prostate. P504S (AMACR, α-methylacyl-CoA racemase) is an essential enzyme in the b-oxidation of branched chain fatty acids. By immunohistochemical staining of paraffin-embedded tissue, it was found that AMACR protein was highly expressed in prostate adenocarcinoma, but not in benign prostate tissue. AMACR expression has also been detected in prostate precancerous lesions, such as prostate intraepithelial neoplasia (PIN). The p63 protein is a homologue of the tumor suppressor p53 and is highly expressed in the basal or progenitor layer of many epithelial tissues. P63 was detected in the prostate basal cells of normal prostate and PIN. However, it is negative in prostate adenocarcinoma. Therefore, p63 can be used as a differential marker (negative marker) for benign prostate and adenocarcinoma. Human AMACR (P504S) protein, α-methylacyl-CoA racemase and human p63 nucleoprotein.